NeoTect False Pos./Neg. Results Preclude Cancer Detection Indication – FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
False positive and false negative findings in the pivotal trials for Diatide’s imaging agent NeoTect (technetium Tc99m depreotide) preclude an indication for identification of malignant pulmonary masses, FDA concluded in review documents.